selpercatinib
1 product
18 abstracts
Abstract
Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC).Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University Hospital, Center for Head and Neck Cancers, Massachusetts General Hospital, Medical Oncology Department. Vall Hebron University Hospital,
Abstract
Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.Org: Cancer Research UK & UCL Cancer Trials Centre, Tohoku Medical Megabank Organization, Taiho Pharmaceutical Co. Ltd, Helsinn Healthcare,
Abstract
Selpercatinib in non-MTC, RET-mutated tumors: Efficacy in MEN-associated and other tumors.Org: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy, Royal North Shore Hospital, St. Leonards, NSW, Australia, Multidisciplinary Oncology & Therapeutic Innovations, Hôpitaux Universitaires de Marseille Timone, Marseille, France, Department of Respiratory Medicine, Nagoya University Graduate school of Medicine, Nagoya, Japan, The Ohio State University Comprehensive Cancer Center, Columbus, OH,
Abstract
Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC).Org: Shanghai Pulmonary Hospital, Shanghai, China, AOU San Luigi, University of Torino, Hospital Ramón y Cajal, University Hospitals KU Leuven,
Abstract
Impact of molecular therapy on radioactive iodine uptake in patients with oncogene-driven metastatic differentiated thyroid cancer.Org: Division of Endocrinology and Diabetes, The Thyroid Center,
Abstract
LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC.Org: Chengdu Institute of Respiratory Health, Branch of National Clinical Research Center for Respiratory Disease, The Third People's Hospital of Chengdu, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf,
Abstract
Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.Org: IDIBELL Medical Oncology,
Abstract
Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.Org: Children’s Cancer Institute, Children's Cancer Centre, Royal Children's Hospital, Seoul National University Children’s Hospital,
Abstract
Efficacy and safety of selpercatinib in advanced RET-altered thyroid cancers: A meta-analysis and systematic review.Org: Nishtar Hospital,
Abstract
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.Org: Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, Lung Cancer Department, The First Affiliated Hospital of Xiamen University,
Abstract
Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC).Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Brigham and Women’s Hospital, Massachusetts General Hospital, Broad Institute of MIT and Harvard,
Abstract
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lombardi Comprehensive Cancer Center, University of Berne and Cantonal Hospital of Lucerne,
Abstract
Using next-generation sequencing for RET fusion detection in Chinese cancer patients.Org: Zhengzhou Third People's Hospital, Zhejiang Shaoxing Topgen Biomedical Technology CO.,LTD,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Genomic mechanisms of RET inhibitor sensitivity and resistance in RET-fusion positive cancer cells.Org: Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, MD Anderson Cancer Center, UT Southwestern Medical Center,
Product
LOXO-292